<DOC>
	<DOCNO>NCT01025466</DOCNO>
	<brief_summary>The primary objective compare tolerability rivastigmine patch monotherapy combination therapy memantine patient Alzheimer 's disease ( AD ) . The secondary objective compare efficacy safety rivastigmine patch monotherapy combination therapy memantine patient AD . The study hypothesis tolerability combination therapy memantine inferior rivastigmine patch monotherapy AD patient .</brief_summary>
	<brief_title>Exelon Patch Combination With Memantine Comparative Trial</brief_title>
	<detailed_description>Recently , rivastigmine patch demonstrate efficacy comparable high dos rivastigmine capsule , markedly improve tolerability profile . We hypothesize combination memantine rivastigmine patch safe well tolerate result clinical benefit patient AD comparison rivastigmine patch monotherapy , mechanisms drug different .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Dementia DSMIV probable AD NINCDSADRDA Age 50 90 year MiniMental State Examination ( MMSE ) score 10 20 Brain MRI CT scan consistent diagnosis probable AD The caregiver must meet patient least week sufficiently familiar patient provide accurate data . Ambulatory ambulatoryaided ( , walker cane ) ability Written inform consent obtain patient ( possible ) patient 's legally acceptable representative . Even unable provide write informed consent , patient must assent verbally participate study . Patients evidence severe unstable physical illness , i.e. , acute severe asthmatic condition , severe unstable cardiovascular disease , active peptic ulcer disease , severe hepatic renal disease , medical condition would prohibit complete study Any psychiatric primary neurodegenerative disorder AD Any patient hear visual problem disturb efficient evaluation patient . Any patient history drug addiction alcohol addiction past 10 year Patients bradycardia ( bpm le 50 ) sick sinus syndrome conduction defect ( sinoatrial block , second ot third degree AV block Clinically significant laboratory abnormality affect cognitive function ( i.e.abnormal thyroid function test , abnormal low level vitamin B12 folate , syphilis , etc ) History allergy topical product contain constitution patch Current diagnosis active skin lesion Involved clinical trial treat experimental drug within 4 week Patients hypersensitivity cholinesterase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2010</verification_date>
</DOC>